Vantage Foundation Brings Smiles and Support to Residents of Victory Old Folks Home in Malaysia
VANTAGE FOUNDATION × TOUCHING LIVES CLUB Community Outreach at Victory Old Folks Home, Puchong KUALA LUMPUR, Malaysia, May 29, 2026 /PRNewswire/ -- At Victory Old Folks Home in Puchong, Malaysia, a karaoke session turned into something more than entertainment. An elderly resident, initially quiet in her wheelchair, began tapping her fingers to the music. By the second song, she...
Doctors at Omotesando Helene Clinic Publish New Study on Long-Term Safety Surveillance Following High-Dose Intravenous MSC Administration
Continuing clinical data analysis and academic publication in regenerative medicine and ATMP as the Tokyo clinical hub within Helene Bio Group TOKYO, May 29, 2026 /PRNewswire/ -- Medical Corporation HELENE Omotesando Helene Clinic, located in Minato-ku, Tokyo, is pleased to announce that a research paper authored by its physicians, Dr. Takaaki Matsuoka and Dr. Nana Kobayashi, has been published in...
HMS Vision Inc. and Wenzhou Medical University Announce the Expansion of Their Simulation-Based Training Center During Vision China 2026
TIANJIN, China, May 29, 2026 /PRNewswire/ -- HMS Vision Inc. announced this week at Vision China 2026 the expansion of the HelpMeSee Simulation-based Eye Surgery Training Program at the Eye Hospital of Wenzhou Medical University (WMU). Since the collaboration began in 2018, the program has grown significantly, and with this latest...
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 29, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-development, and co-commercialization opportunities across...
Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026...
Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented. The efficacy data highlight how the combination of elacestrant and capivasertib has the potential to address key resistance mechanisms for patients with ER+/HER2- mBC, including ESR1 and PIK3CA co-existing mutations. The...
Sino Biological’s Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab’s Protein Design Study Published in Nature Communications
HOUSTON, May 28, 2026 /PRNewswire/ -- Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) has announced that its gene synthesis and cell-free protein expression workflow was used in a recent study by Tencent AI for Life Sciences Lab published in Nature Communications, enabling rapid validation of AI-designed proteins with improved activity, stability, and multifunctionality. Bridging AI Protein Design and...
Haier Biomedical Achieves Double No. 1 Ranking in Euromonitor’s Global Life Science Lab Equipment Report, Caps Three-Phase Global Expansion
QINGDAO, China, May 28, 2026 /PRNewswire/ -- Haier Biomedical (SHA: 688139) has been named the No. 1 Chinese brand in global life science laboratory equipment sales and No. 1 in overseas sales in the same category, according to 2025 data published by Euromonitor International. The dual ranking places Haier Biomedical at the...
NYSE Content Update: Hinge Health Shares Up 72% One Year from its IPO
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 28, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Snowflake...
China-US Dual Filing Success: Porton Advanced’s End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors’ Innovative Oncolytic Bacteria Therapy
CRANBURY, N.J. and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Porton Advanced, a leading cell and gene therapy CDMO, recently announced its client Salvectors has received Investigational New Drug (IND) clearance for their proprietary and innovative oncolytic bacteria therapy, "YB1-X7 Injection," from the Center for Drug Evaluation of China's National Medical Products Administration (NMPA). YB1-X7 has now successfully obtained...
POMDOCTOR LIMITED Announces Plan to Implement ADS Ratio Change
GUANGZHOU, China, May 28, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") to its Class A ordinary shares (the "ADS Ratio Change"), from the current ratio of one (1) ADS representing one-sixth...
